These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30707391)

  • 1. Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.
    Gale S; Trinh H; Tuckwell K; Collinson N; Stone JH; Sarsour K; Pei J; Best J; Birchwood C; Mohan SV
    Rheumatol Ther; 2019 Mar; 6(1):77-88. PubMed ID: 30707391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
    Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
    Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources.
    Monemi S; Berber E; Sarsour K; Wang J; Lampl K; Bharucha K; Pethoe-Schramm A
    Rheumatol Ther; 2016 Dec; 3(2):337-352. PubMed ID: 27747579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
    Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
    Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice.
    Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Prieto-Peña D; Atienza-Mateo B; Patiño E; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Loricera J; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):112-119. PubMed ID: 32441643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
    Sakai R; Cho SK; Nanki T; Watanabe K; Yamazaki H; Tanaka M; Koike R; Tanaka Y; Saito K; Hirata S; Amano K; Nagasawa H; Sumida T; Hayashi T; Sugihara T; Dobashi H; Yasuda S; Sawada T; Ezawa K; Ueda A; Fujii T; Migita K; Miyasaka N; Harigai M;
    Arthritis Res Ther; 2015 Mar; 17(1):74. PubMed ID: 25880658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
    Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
    Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
    Soubrier M; Pei J; Durand F; Gullestad L; John A
    Rheumatol Ther; 2017 Jun; 4(1):133-149. PubMed ID: 27900570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
    Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.
    Curtis JR; Perez-Gutthann S; Suissa S; Napalkov P; Singh N; Thompson L; Porter-Brown B;
    Semin Arthritis Rheum; 2015 Feb; 44(4):381-8. PubMed ID: 25300699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
    Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
    Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.
    Samec MJ; Rakholiya J; Langenfeld H; Crowson CS; Abril A; Wang B; Mertz L; Rodriguez-Pla A; Bansal P; Burke M; Jaquith J; Weyand C; Warrington KJ; Koster MJ
    J Rheumatol; 2023 Oct; 50(10):1310-1317. PubMed ID: 37321636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.
    Calderón-Goercke M; Loricera J; Moriano C; Castañeda S; Narváez J; Aldasoro V; Maiz O; Melero R; Villa JI; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sanchéz-Martín J; Sánchez-Bilbao L; González-Gay MA; Hernández JL; Blanco R;
    Clin Exp Rheumatol; 2023 Apr; 41(4):829-836. PubMed ID: 36377586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.
    de Boysson H; Le Besnerais M; Blaison F; Daumas A; Jarrot PA; Perrin F; Tieulié N; Maria A; Duffau P; Gombert B; Samson M; Espitia O; Lambert M; Mékinian A; Aouba A;
    Arthritis Res Ther; 2021 May; 23(1):143. PubMed ID: 34011407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.
    Matza MA; Dagincourt N; Mohan SV; Pavlov A; Han J; Stone JH; Unizony SH
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37024237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK.
    Gale S; Wilson JC; Chia J; Trinh H; Tuckwell K; Collinson N; Dimonaco S; Jick S; Meier C; Mohan SV; Sarsour K
    Rheumatol Ther; 2018 Dec; 5(2):327-340. PubMed ID: 29752705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies.
    Haraoui B; Casado G; Czirják L; Taylor A; Dong L; Button P; Luder Y; Caporali R
    Rheumatol Ther; 2019 Jun; 6(2):231-243. PubMed ID: 30859494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A
    Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
    Nielsen MK; Nielsen AW; Donskov AO; Hansen IT; Nielsen BD; Mørk C; Hauge EM; Keller KK
    Semin Arthritis Rheum; 2024 Oct; 68():152508. PubMed ID: 38981187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.